drugset / Trial / NCT01051466

A Study of the Neurobiology of Depression

NCT01051466

Phase 4 Completed 60 enrolled Eli Lilly and Company
Non-randomizedParallel-groupOpen-labelBasic science

Summary

Previous research studies have shown that depression is associated with changes in structure and activity in different parts of the brain and that antidepressant medication can affect brain activity in different parts of the brain in individuals suffering from depression. The primary purpose of the study is to find out more about how the antidepressant medication duloxetine affects brain activity and structure in individuals with depression.

Timeline

Start
2010-01
Primary completion
2013-03
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Duloxetine Small molecule 60 mg Oral
Subject Duloxetine Small molecule 120 mg Oral